Lappaconitine Hydrobromide Injection

Accessories: phosphate buffer, activated carbon (for injection).
【 characteristics 】 this product is colorless transparent liquid.
【 indications 】 used for moderate pain.
【 specification 】 2 ml: 4 mg 【 usage and dosage 】 intramuscular injection: a 4 mg, 1 ~ 2 times a day, or as directed by your doctor.
Intravenous drip: 1, 4 ~ 8 mg, dissolved in glucose and sodium chloride injection 500 ml static drops.
【 side effect 】 individual patients with urticaria, flustered, chest tightness, dizziness, etc., soon disappeared after drug withdrawal.
【 taboo 】 it is not clear.
【 notes 】 【 poisoning is the early performance of electrocardiogram (ecg) changes (reversible).
Not pregnant women and nursing mothers medication 】 【 and beyond by reference to the experiment.
Medicine for children 【 】 this product is used for children's safety and efficacy have not been established.
Not for the elderly medication 】 【 experiment and beyond by reference.
[drug interaction] did not conduct the experiment and beyond by reference.
Without drug overdose 】 【 and beyond by reference to the experiment.
This product is not addictive pharmacology and toxicology 】 【 pharmacology analgesics, with strong analgesic action.
This product also has a local anesthetic, cooling, antipyretic and anti-inflammatory swelling effect.
This product compared with pethidine, analgesic effect, working time is a bit slow, and maintain for a long time;
Analgesic effects of antipyretic analgesics amidopyrine seven times.
Toxicology of this product without addiction, not consultations with animal testing, also won't happen accumulation poisoning.
Results: acute toxicity test in rats by oral LD50 to 20 mg/Kg;
Mice celiac injection of LD50 is 9.1 mg/Kg, intravenous LD50 was 6.9 mg/Kg.